Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Mann

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 2, 2012
Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumoursYongqiang Tan, Pingzhen Guo, Helen Mann, et al.
European Journal of Radiology|March 16, 2013
Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervalsBinsheng Zhao, Yongqiang Tan, Daniel J Bell, et al.
Cancer|January 26, 2008
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancerFred R Hirsch, Rafal Dziadziuszko, Nick Thatcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan, Anderson J Ryan, Helen Mann, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2019
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic ImpairmentEnrique Grande, R Donald Harvey, Benoit You, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Parkinson'S Disease|September 20, 2021
Driving and Parkinson's Disease: A Survey of the Patient's PerspectivePeter Brock, Lloyd L Oates, William K Gray, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancerByoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, et al.
Cancer Science|September 21, 2025
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC TrialYoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, et al.
Clinical Lung Cancer|July 23, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)Mark A Socinski, Mustafa Özgüroğlu, Augusto Villegas, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 2, 2012
Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumoursYongqiang Tan, Pingzhen Guo, Helen Mann, et al.
European Journal of Radiology|March 16, 2013
Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervalsBinsheng Zhao, Yongqiang Tan, Daniel J Bell, et al.
Cancer|January 26, 2008
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancerFred R Hirsch, Rafal Dziadziuszko, Nick Thatcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancerEmer O Hanrahan, Anderson J Ryan, Helen Mann, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 16, 2019
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic ImpairmentEnrique Grande, R Donald Harvey, Benoit You, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Parkinson'S Disease|September 20, 2021
Driving and Parkinson's Disease: A Survey of the Patient's PerspectivePeter Brock, Lloyd L Oates, William K Gray, et al.
Lung Cancer (Amsterdam, Netherlands)|December 11, 2025
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancerByoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, et al.
Cancer Science|September 21, 2025
Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC TrialYoshitaka Zenke, Yoshimasa Shiraishi, Yasushi Goto, et al.
Clinical Lung Cancer|July 23, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)Mark A Socinski, Mustafa Özgüroğlu, Augusto Villegas, et al.
Pageof 6